DS-2325a
Sponsors
Daiichi Sankyo Inc., Daiichi Sankyo
Conditions
Netherton SyndromeNetherton's Syndrome
Phase 1
A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects
CompletedNCT05388903
Start: 2022-06-20End: 2023-01-26Updated: 2023-03-06
A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects
CompletedNCT05583669
Start: 2022-11-08End: 2023-05-11Updated: 2023-05-18
A Phase 1b/2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Arm Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients with Netherton Syndrome
CompletedCTIS2022-502853-32-00
Start: 2023-08-18End: 2025-01-06Target: 12Updated: 2024-10-15
A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome
TerminatedNCT05979831
Start: 2023-09-28End: 2025-01-06Updated: 2025-01-20